Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PMA Immunotherapy for Perennial Allergic Rhinitis
NCT03360071Phase 2Completed
- Sponsor
- Johns Hopkins University
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 12-o-tetradecanoylphorbol-13-acetate in perennial allergic rhinitis (PAR), sponsored by Johns Hopkins University. Started Dec 2016; status: completed.
02
Drugs
12-o-tetradecanoylphorbol-13-acetate
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT03360071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03360071.